MULHOUSE, France & SAN CARLOS, Calif.--(BUSINESS WIRE)--CellProThera® and BioCardia® today announced an agreement to partner on the EXCELLENT (Expanded Cell Endocardiac Transplantation) Trial, a multi-center, controlled Phase I/IIb study to evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process and delivered via the BioCardia Helix™ Transendocardial Delivery System.
The agreement calls for milestone payments to BioCardia, which are creditable to a future clinical development program, and milestone payments to CellProThera for timely completion of the Phase II study.
Help employers find you! Check out all the jobs and post your resume.
